Placental niche and use thereof to culture stem cells
The present invention provides methods for culturing, expanding and differentiating stem cells, particularly human embryonic stem cells. The methods comprise culturing the stem cells for a period of time on a collagen biofabric, particularly a collagen biofabric derived from the amniotic membrane, chorion, or both, from mammalian placenta.
1 . A method of culturing a stem cell comprising culturing the stem cell in a culture medium with a collagen biofabric, wherein said collagen biofabric is derived from a placenta, and said stem cell is exogenous to said collagen biofabric.
2 . The method of claim 1 wherein said collagen biofabric comprises an amniotic membrane and/or a chorion isolated from a mammalian placenta.
3 .- 4 . (canceled)
5 . The method of claim 1 , wherein said collagen biofabric is substantially dry prior to said culturing.
6 . The method of claim 1 , wherein said collagen biofabric is decellularized prior to said culturing, or wherein said collagen biofabric is not decellularized prior to said culturing.
7 . (canceled)
8 . The method of claim 1 , wherein said collagen biofabric further comprises cells endogenous or exogenous to a placenta from which the collagen biofabric is derived.
9 . (canceled)
10 . The method of claim 8 , wherein said collagen biofabric is irradiated.
11 .- 13 . (canceled)
14 . The method of claim 1 , wherein said stem cell is an embryonic stem cell, a placental stem cell, a mesenchymal stem cell, a hematopoietic stem cell, a placental blood- or umbilical cord blood-derived stem cell, a bone marrow-derived stem cell, or an adult somatic stem cell.
15 . The method of claim 14 , wherein said adult somatic stem cell is a neural stem cell, a hepatic stem cell, a pancreatic stem cell, an endothelial stem cell, a cardiac stem cell, or a muscle stem cell.
16 . The method of claim 1 , wherein said stem cell is cultured for 24 hours or more, two days or more, or seven days or more.
17 .- 18 . (canceled)
19 . A method of differentiating a stem cell comprising culturing said cell in culture medium with a collagen biofabric for a time sufficient for differentiation of the cell.
20 . The method of claim 19 , wherein said collagen biofabric comprises an amniotic membrane and/or a chorion isolated from a mammalian placenta.
21 .- 22 . (canceled)
23 . The method of claim 19 , wherein said collagen biofabric is substantially dry prior to said differentiating.
24 . The method of claim 19 , wherein said collagen biofabric is decellularized prior to said differentiating, or wherein said collagen biofabric is not decellularized prior to said culturing.
25 . (canceled)
26 . The method of claim 19 , wherein said collagen biofabric further comprises cells endogenous or exogenous to a placenta from which the collagen biofabric is derived.
27 . (canceled)
28 . The method of claim 19 , further comprising culturing a somatic cell on said collagen biofabric.
29 .- 30 . (canceled)
31 . The method of claim 19 , wherein said stem cell is an embryonic stem cell, a placental stem cell, a mesenchymal stem cell, a hematopoietic stem cell, a placental blood- or umbilical cord blood-derived stem cell, a bone marrow-derived stem cell, or an adult somatic stem cell.
32 . The method of claim 31 , wherein said adult somatic stem cell is a neural stem cell, a hepatic stem cell, a pancreatic stem cell, an endothelial stem cell, a cardiac stem cell, or a muscle stem cell.
33 . The method of claim 19 , wherein said cell is differentiated into a neural cell, an adipocyte, a chondrocyte, an osteocyte, a hepatocyte, a pancreatic cell, or a cardiac cell.
34 . A method of determining the toxicity of a compound to a cell, comprising culturing said cell with a collagen biofabric under conditions suitable for the survival of the cell; contacting said cell with the compound; and identifying a change in a metabolic parameter of said cell indicating apoptosis, necrosis, or cell death, or a tendency towards apoptosis, necrosis or cell death, as compared to a cell cultured under equivalent conditions and not contacted with said compound, wherein if said change is identified, said compound is toxic to said cell.
35 . (canceled)
36 . The method of claim 1 , wherein said collage biofabric comprises hyaluronic acid, or wherein said collage biofabric comprises hyaluronic acid and wherein said hyaluronic acid is crosslinked to said collagen biofabric.
37 . (canceled)